Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …

Dear Editor, Since the first outbreak in late 2019, the RNA genome of SARS-CoV-2 has
been undergoing constant evolution. This is largely attributed to the viral polymerase that is …

Background Molnupiravir was granted emergency use authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based …

Background: A randomized controlled trial involving a high-risk, unvaccinated population
that was conducted before the Omicron variant emerged found that nirmatrelvir–ritonavir …

Background Using a retrospective cohort study design, we aimed to evaluate the
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …

Background We examined the effectiveness of molnupiravir and nirmatrelvir/ritonavir in
reducing hospitalization and deaths in a real-world cohort of nonhospitalized patients with …

Introduction There is limited real-world evidence surrounding the effectiveness of early, mild-
to-moderate COVID-19 treatments following the emergence and dominance of Omicron …

Background: Whether hospitalized patients benefit from COVID-19 oral antivirals is
uncertain. Objective: To examine the real-world effectiveness of molnupiravir and …

Objective To emulate a randomized target trial to estimate the association between the
antiviral drug molnupiravir and hospital admission or death in adults with SARS-CoV-2 …

Background Nirmatrelvir is a protease inhibitor with in-vitro activity against SARS-CoV-2,
and ritonavir-boosted nirmatrelvir can reduce the risk of progression to severe COVID-19 …